Physician Education: Bridging Clinical Research and Patient Care

Faculty Profile

Associate Professor
The University of Alabama at Birmingham School of Medicine
Division of Clinical Pharmacology
Birmingham, AL

Topics of Professional Interest:
  • Understanding the absorption and disposition characteristics of antiviral and antiretroviral drugs in adults and pediatric patients, both domestically and internationally
  • Developing assays using HPLC-UV, LC/MS, and LC/MS/MS methodologies to quantitate antiviral and antiretroviral drugs in various biological matrices
  • Applying novel pharmacokinetic and pharmacodynamic models and simulations to clinical trials using rational study designs
  • Understanding the basic, translational, and clinical pharmacology of drugs in pregnant women and their infants, and other populations
  • Clinical pharmacology (pharmacokinetics and pharmacodynamics) of antiviral and antiretroviral drugs
  • Drug-drug interactions of antiretroviral compounds
Current Professional Summary:

Dr Acosta is Associate Professor in the Division of Clinical Pharmacology at the University of Alabama at Birmingham School of Medicine. He is the Principal Investigator of the Adult Pharmacology Support Laboratory (PSL) and the Pediatric Pharmacology Core Laboratory of the AIDS Clinical Trials Group (ACTG) at UAB. Dr Acosta has longstanding experience in the clinical pharmacology of antiviral and antiretroviral agents in adult and pediatric patients and runs a CLIA-certified laboratory. He is protocol pharmacologist or co-chair on numerous ACTG studies, serves as Chair of the Pediatric ACTG Pharmacology Committee, and was recent Chair of the Adult ACTG PSL Subcommittee. He also serves as pharmacologist to the Collaborative Antiviral Study Group. Through these trial networks, he designs, implements, and analyzes clinical pharmacology data collected from multicenter clinical studies.

Dr Acosta has published articles in peer-reviewed journals and has made presentations and submitted abstracts related to HIV and AIDS at the Interscience Conference on Antimicrobial Agents and Chemotherapy, the Conference on Retroviruses and Opportunistic Infections, and the International Conference on AIDS. He also teaches first- and second-year UAB medical students antivirals and antiretrovirals, and he lectures graduate students on the concepts of pharmacokinetics and pharmacodynamics.

Committees and Organizations:
  • Editorial board, Journal of Acquired Immune Deficiency Syndromes (JAIDS) (2004–Present)
  • American Society for Microbiology (1994–Present)
  • American Society for Clinical Pharmacology and Therapeutics
  • International Society for Antiviral Research
  • Chair, Pediatric Pharmacology Committee of the PACTG (2004–2006)
Honors and Awards:
  • American Society for Microbiology Fellow Travel Grant Award (1995)
  • American Society for Microbiology Fellow Travel Grant Award (1994)
  • Miles Pharmaceuticals Research Fellowship Award in Infectious Diseases Therapeutics (1993)
Education:
  • University of Minnesota Duluth, BA Biology (1984–1988)
  • University of Minnesota, Minneapolis, BS Pharmacy (1988–1991)
  • University of Minnesota, Minneapolis, PharmD (1988–1992)
  • University of Minnesota, Minneapolis, Post-doctoral Research Fellowship in Infectious Diseases (1992–1994)
Selected Publications:
  1. Gulick RM, Robaudo HJ, Shikuma CM, Lustgarten S, Squires KE, Meyer III WA, Acosta EP, et al. Triple nucleoside analogue vs. efavirenz-containing regimens for the initial treatment of HIV-1 infection: AIDS Clinical Trials Group (ACTG) Study A5095. N Engl J Med. 2004;350-1850-1861.
  2. Acosta EP, Bardeguez A, Zorrilla CD, et al. Pharmacokinetics of squinavir plus low-dose ritonavir in HIV-infected pregnant women. Antimicrob Agents Chemother. 2004;48:430-436.
  3. Acosta EP, King JR. Methods for integration of pharmacokinetic and phenotypic information in the treatment of HIV infection. Clin Infect Dis. 2003;36:373-377.
  4. Acosta EP, Balfour HJ Jr. Intermittent administration of high-dose stavudine to nucleoside-experienced individuals. J Acquir Immune Defic Syndr. 2003;33:343-348.
  5. Turner ML, Reed-Walker K, King JR, Acosta EP. Simultaneous quantitation of protease inhibitors and non-nucleoside reverse transcriptase inhibitors in human plasma using a single high-performance liquid chromatography methodology. J Chromatogr B. 2003;784:331-341.
  6. King JR, Nachman S, Yogev R, Aldrovandi G, Damle B, Hodge J, Wiznia A, Acosta EP, for the PACTG Group 403 Team. Single-dose pharmacokinetics of enteric-coated didanosine in HIV-infected children. Antiviral Ther. 2002;7:267-270.
  7. Acosta EP, Balfour HH Jr. Acyclovir for treatment of postherpetic neuralgia: efficacy and pharmacokinetics. Antimicrob Agents Chemother. 2001;45:2771-2774.
  8. Acosta EP, Zorrilla CD, Van Dyke R, et al. Pharmacokinetics of saquinavir-sgc in HIV-infected pregnant women. HIV Clin Trials. 2001;2:460-465.
  9. Acosta EP, Gerber JG, and the Adult ACTG Pharmacology Committee. Position paper on therapeutic drug monitoring of antiretroviral agents. AIDS Res Hum Retroviruses. 2002;18:825-834.
  10. Acosta EP, Kakuda TN, Brundage RC, Anderson PL, Fletcher CV. Pharmacodynamics of human immunodeficiency virus type 1 protease inhibitors. Clin Infect Dis. 2000;30(suppl):S151-S159.